Search Results - "He, A.R"

525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028 by Bang, Y.J, Doi, T, Braud, F. De, Piha-Paul, S, Hollebecque, A, Razak, A.R. Abdul, Lin, C.C, Ott, P.A, He, A.R, Yuan, S.S, Koshiji, M, Lam, B, Aggarwal, R

Get full text

86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study by He, A.R., Valle, J.W., Lee, C-K., Ikeda, M., Potemski, P., Morizane, C., Cundom, J.E., Tougeron, D., Dayyani, F., Rokutanda, N., Xiong, J., Cohen, G., Oh, D-Y.

Get full text

102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study by He, A.R., Bouattour, M., Gupta, V.G., Evesque, L., Zhen, D.B., Park, J.O., Sookprasert, A., Salvatierra, A., Vaccaro, G.M., Oh, S.C., Ostoich, S.A., Satoh, T., Żotkiewicz, M., Rokutanda, N., Kim, H., Oh, D-Y.

Get full text

960P Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC) by Abdelrahim, M., Esmail, A., He, A.R., Franses, J., Bhan, I., Victor, D.W., Kodali, S., Connor, A.A., Saharia, A., Brdiges, C., Tin, T., Brewer, C., Jurdi, A., Liu, M.C., Ghobrial, R.M.

Get full text

418 POSTER A phase I trial of GMX1777: an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT) by Pishvaian, M.J, Hwang, J.H, Malik, S, He, A.R, Deeken, J.F, Kelso, C.B, Dorsch-Vogel, K, Berger, M.S, Marshall, J.L

Get full text

Circulating tumor DNA monitoring for recurrence detection and treatment response assessment in HCC by Abdelrahim, M., Esmail, A., He, A.R., Victor, D., Kodali, S., Connor, A.A., Saharia, A., Bridges, C., Tin, A., Brewer, C., Aushev, V., Jurdi, A., Liu, M.C., Ghobrial, R.M.

Get full text

Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463] by Oh, D., He, A.R., Qin, S., Chen, L., Okusaka, T., Vogel, A., Kim, J.W., Suksombooncharoen, T., Lee, M.A., Kitano, M., Burris, H.A., Bouattour, M., Tanasa, S., Zaucha, R.E., Avallone, A., Cundom, J.E., Rokutanda, N., Żotkiewicz, M., Cohen, G., Valle, J.W.

Get full text

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 by Melero, I, Yau, T, Kang, Y-K, Kim, T-Y, Santoro, A, Sangro, B, Kudo, M, Hou, M-M, Matilla, A, Tovoli, F, Knox, J, He, A R, El-Rayes, B, Acosta-Rivera, M, Lim, H Y, Soleymani, S, Yao, J, Neely, J, Tschaika, M, Hsu, C, El-Khoueiry, A B

“…Nivolumab plus ipilimumab demonstrated promising clinical activity and durable responses in sorafenib-treated patients with advanced hepatocellular carcinoma…”
Get more information

409 POSTER A Phase I clinical trial of the oral PPAR gamma agonist, CS-7017 in patients with advanced malignancies by Pishvaian, M.J, Wagner, A, Deeken, J, He, A.R, Hwang, J, Malik, S, Cotarla, I, Demetri, G, Marshall, J.L, Wojtowicz-Praga, S

Get full text

83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) by Chan, S.L., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Ran, D., Negro, A., Abou-Alfa, G.K.

Get full text

67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) by Chan, S.L., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Gupta, C., Negro, A., Abou-Alfa, G.K.

Get full text

78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC) by Oh, D-Y., He, A.R., Qin, S., Chen, L-T., Okusaka, T., Vogel, A., Kim, J.W., Lee, T., Lee, M.A., Kitano, M., Burris, H.A., Bouattour, M., Tanasanvimon, S., Zaucha, R.E., Avallone, A., Cundom, J.E., Rokutanda, N., Żotkiewicz, M., Cohen, G., Valle, J.W.

Get full text

56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC) by Oh, D-Y., He, A.R., Qin, S., Chen, L-T., Okusaka, T., Vogel, A., Kim, J.W., Suksombooncharoen, T., Lee, M.A., Kitano, M., Burris, H.A., Bouattour, M., Tanasanvimon, S., Zaucha, R.E., Avallone, A., Cundom, J.E., Rokutanda, N., Watras, M., Cohen, G., Valle, J.W.

Get full text

714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) by Chan, L.S., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J-W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Cheng, A-L., Azevedo, S., Reig Monzon, M.E., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Ran, D., Negro, A., Abou-Alfa, G.K.

Get full text

A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 by Oh, D.-Y., Chen, L.-T., He, A.R., Okusaka, T., Qin, S., Chin, S., Rokutanda, N., Uchinda, H., Vogel, A., Valle, J.W., Kim, H.

Get full text

831TiP - A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 by Oh, D.-Y., Chen, L.-T., He, A.R., Okusaka, T., Qin, S., Chin, S., Rokutanda, N., Uchinda, H., Vogel, A., Valle, J.W., Kim, H.

“…Advanced, unresectable biliary tract cancer (BTC) represents an area of unmet medical need due to its aggressive nature, limited treatment options, and poor…”
Get full text

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling by Lin, L, Amin, R, Gallicano, G I, Glasgow, E, Jogunoori, W, Jessup, J M, Zasloff, M, Marshall, J L, Shetty, K, Johnson, L, Mishra, L, He, A R

“…Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide, with few effective therapeutic options for advanced disease. At least 40%…”
Get full text

Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study by Lee, K.-H., Hsu, C.-H., Lee, M.S., Ryoo, B.-Y., Verret, W., He, A.R., Kwan, A., Liu, B., Iizuka, K., Stein, S.

Get full text

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study by He, A.R., Weiss, G.J., Falchook, G., Yee, N.S., Gil-Martin, M., Shahda, S., Moreno, V., Brana, I., Crittenden, M., Formenti, S., Al-Rajabi, R., Papadopoulos, K.P., Pishvaian, M.J., Stankevich, E., Feng, M., Li, J., Mathias, M., Kroog, G., Lowy, I., Fury, M.G.

Get full text

Stability analysis of transversely isotropic laminated Mindlin plates with piezoelectric layers using a Levy-type solution by Ghasemabadian, M.A, Saidi, A.R

“…In this paper, based on the first-order shear deformation plate theory, buckling analysis of piezoelectric coupled transversely isotropic rectangular plates is…”
Get full text